Abstract
Amgen is the world's largest biotechnology company and the eighth largest
pharmaceutical company worldwide. Revenues have nearly doubled in the last
three years, going from $5.52 billion in 2002 to $10.55 billion in 2004. Yet
the majority of revenue is based on twenty-year old technology. Can Amgen
continue its amazing revenue growth? Or will it fall behind, lacking the small
molecule therapeutics that are the mainstay of modern pharmaceuticals?
This report provides an in-depth analysis of Amgen's
- Strategic strengths and weaknesses
- Current therapeutic products and pipeline of future products
- Financial analysis, including R& D productivity
- Current patents and patent applications
- Alliances, joint ventures and acquisitions
- Key personnel
Who should buy this report?
- Biotech and pharmaceutical companies of all sizes interested in
understanding Amgen's
- rapid climb to success and its future direction
- Early stage biotechnology companies interested in understanding Amgen
Ventures strategy for investing its $100 million
- Financial analysts looking for an in-depth technical analysis of Amgen's
future revenue sources
Key reasons to purchase this report
- Competitive intelligence
- Benchmark company performance against the leading biotechnology company
- Understand what is driving Amgen's growth, and what is holding it back
This 81 page up-to-date report, based on information gathered through the end
of the first quarter 2005, contains five tables on Amgen's pipeline; a listing
of the last three years of granted patents, analyzed by therapeutic area as
well as therapeutic form; a breakdown of sales for all key products; both U.S.
and International, as well as a list of all patent applications for 2004
through the first quarter of 2005.
View Cart
